透明质酸载体靶向治疗消化系肿瘤的研究进展  

Targeted therapy of gastrointestinal tumors using hyaluronic acid drug carriers

作　　者：吴道澄[1] 顾雪凡[1,2] 

机构地区：[1]西安交通大学生物医学信息工程教育部重点实验室,陕西省西安市710049 [2]西安石油大学化学化工学院,陕西省西安市710065

出　　处：《世界华人消化杂志》2012年第32期3075-3080,共6页World Chinese Journal of Digestology

基　　金：国家重点基础研究发展973计划基金资助项目;No.2010CB732603;国家自然科学基金资助项目;No.20905060;No.30970712~~

摘　　要：透明质酸(hyaluronic acid,HA)是一种生物相容性好、可生物降解的天然线性多糖,近年来发现肿瘤细胞表面存在HA特异性受体.因此,利用HA及其衍生物的可降解性及细胞表面HA受体专一性等特性,将HA及其衍生物制成药物载体可达到药物缓释和靶向运输的目的.目前HA靶向治疗主要集中在前列腺、肺和头颈部肿瘤等方面,消化系肿瘤仅有结肠癌的报道,其肿瘤靶向性具体机制的诸多细节尚未搞清.本文主要评述了HA靶向载体的设计、性质及其在靶向治疗消化系肿瘤方面的进展,还对该体系的前景进行了预测.Hyaluronic acid（HA） is a natural,linear,high molecular weight mucopolysaccharide with good biocompatibility and biodegradability.Recently,HA receptor has been found on the surface of tumor cells.Therefore,sustainedrelease and tumor-targeting drug carriers with hyaluronic acid and its derivatives have been fabricated,because they can bind specifically to the HA receptor on the surface of tumor cells and are biodegradable.Now,the research on targeted therapy using hyaluronic acid drug carriers is focused on the therapy of prostatic cancer,pulmonary cancer and head and neckneoplasms.Colon tumors are the only type of gastrointestinal tumors in which hyaluronic acid drug carriers were studied.In this paper,we introduce the design and characteristics of hyaluronic acid drug carriers and review recent progress and future prospects of targeted treatment of gastrointestinal tumors using hyaluronic acid drug carriers.

关 键 词：透明质酸 药物载体 靶治疗 消化系肿瘤 

分 类 号：R735[医药卫生—肿瘤]